OKUR - NASDAQ
OnKure Therapeutics, Inc.
$4.30
+4.4%OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
At a Glance
Live Snapshotokur
Cash at Beginning of Period
Last Annual Value
110.76M
3-Year CAGR
103%
5-Year CAGR
45%
10-Year CAGR
20%
OnKure Therapeutics, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 OnKure Therapeutics, Inc. NASDAQ:OKUR | 110.76M | 112.5% | 15.6% | N/A | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 41.69B | 726.6% | 328.6% | 78.1% | |
 Kezar Life Sciences, Inc. NASDAQ:KZR | 41.75M | 1.1% | 14.5% | 7.8% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 37.11M | -23.1% | -30.0% | N/A | |
 CEL-SCI Corporation AMEX:CVM | 4.15M | -43.2% | -23.2% | -3.2% | |
 Xilio Therapeutics, Inc. NASDAQ:XLO | 57.07M | -22.0% | 22.4% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 76.99M | -11.0% | 3.8% | 11.6% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 175.04M | 10.6% | -7.3% | 31.3% |
OnKure Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your OKUR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.